il-2
Showing 26 - 50 of 60
Carcinoma, Renal Cell Trial in Houston (TroVax, IL-2)
Completed
- Carcinoma, Renal Cell
- TroVax
- IL-2
-
Houston, TexasThe Methodist Hospital
Oct 9, 2020
Acute Myeloid Leukemia, Leukemia, Myeloid Leukemia Trial in Spain (cyclophosphamide, Fludarabine, NK cell infusion)
Completed
- Acute Myeloid Leukemia
- +2 more
- cyclophosphamide
- +3 more
-
Barakaldo, Vizcaya, Spain
- +5 more
Oct 1, 2020
Ewing's Sarcoma, Rhabdomyosarcoma Trial run by the NCI (EF-1 Peptide, EF-2 Peptide, PXFK Peptide)
Completed
- Ewing's Sarcoma
- Rhabdomyosarcoma
- EF-1 Peptide
- +7 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 27, 2019
Lymphoma, B-cell Lymphoma Trial in Houston (Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion)
Completed
- Lymphoma
- B-cell Lymphoma
- Leukapheresis
- +7 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jun 27, 2020
Infection in Treatment of Low-dose IL-2 of SLE Patients
Unknown status
- Infection
- IL-2
-
Beijing, Beijing, ChinaPeking Universtiy People's Hospital
Oct 21, 2019
Metastatic Renal Cell Carcinoma Trial in United States (Hydroxychloroquine, IL-2)
Completed
- Metastatic Renal Cell Carcinoma
- Hydroxychloroquine
- IL-2
-
Maywood, Illinois
- +6 more
Dec 24, 2019
Melanoma Trial in Houston (Vemurafenib, IL-2, Interferon Alpha-2b)
Completed
- Melanoma
- Vemurafenib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 17, 2019
Metastatic Renal Cell Carcinoma Trial (PD-1 Knockout T Cells, Cyclophosphamide, IL-2)
Withdrawn
- Metastatic Renal Cell Carcinoma
- PD-1 Knockout T Cells
- +2 more
- (no location specified)
Mar 4, 2019
PD-1 Knockout Engineered T Cells for Castration Resistant
Withdrawn
- Hormone Refractory Prostate Cancer
- PD-1 Knockout T Cells
- +2 more
-
Beijing, Beijing, ChinaDepartment of Urology Peking University First Hospital
Mar 4, 2019
Invasive Bladder Cancer Stage IV Trial in Beijing (PD-1 Knockout T Cells, Cyclophosphamide, IL-2)
Withdrawn
- Invasive Bladder Cancer Stage IV
- PD-1 Knockout T Cells
- +2 more
-
Beijing, Beijing, ChinaDepartment of Urology Peking University First Hospital
Mar 4, 2019
Malignant Melanoma Stage IV Trial in Ramat Gan (Fludarabine, Cyclophosphamide, TIL)
Unknown status
- Malignant Melanoma Stage IV
- Fludarabine
- +3 more
-
Ramat Gan, IsraelSheba Medical Center
Apr 3, 2019
Metastatic Ovarian Cancer Trial in Ramat Gan (drug, radiation, biological)
Unknown status
- Metastatic Ovarian Cancer
- Fludarabine
- +3 more
-
Ramat Gan, IsraelSheba medical Center
Apr 3, 2019
Depression Trial in Atlanta (Escitalopram, Placebo, IL-2)
Metastatic Colorectal Cancer Trial in Fuzhou (Irinotecan, Oxaliplatin, Levoleucovorin)
Withdrawn
- Metastatic Colorectal Cancer
- Irinotecan
- +5 more
-
Fuzhou, Fujian, ChinaRongbo Lin
Mar 23, 2018
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma Trial in Lebanon (GM-CSF, IL-2)
Completed
- Non-Hodgkin's Lymphoma
- +4 more
- GM-CSF
- IL-2
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Apr 23, 2018
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Minneapolis (Fludarabine, Cyclophosphamide,
Completed
- Ovarian Cancer
- +3 more
- Fludarabine
- +6 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Dec 3, 2017
Hepatocellular Carcinoma Trial in Beijing (iNKT cells, IL-2, Tegafur)
Unknown status
- Hepatocellular Carcinoma
- iNKT cells
- +2 more
-
Beijing, Beijing, ChinaBeijing Youan Hospital,Capital Medical University
Jan 17, 2018
Hepatocellular Carcinoma Trial in Beijing (HCC antigens-specific CD8+ T lymphocytes, IL-2, Tegafur)
Unknown status
- Hepatocellular Carcinoma
- HCC antigens-specific CD8+ T lymphocytes
- +2 more
-
Beijing, Beijing, ChinaBeijing Youan Hospital,Capital Medical University
Jan 17, 2018
Leukemia, Myelogenous, Acute Trial in Minneapolis (biological, drug, procedure)
Terminated
- Leukemia, Myelogenous, Acute
- Natural Killer Cells
- +5 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Dec 3, 2017
Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma Trial in Minneapolis (Fludarabine, Cyclophosphamide, NK
Completed
- Ovarian Cancer
- +2 more
- Fludarabine
- +4 more
-
Minneapolis, MinnesotaUniversity of Minnesota Masonic Cancer Center
Dec 3, 2017
Graft-Versus-Host-Disease Trial in Tampa (IL-2, Tacrolimus, Sirolimus)
Completed
- Graft-Versus-Host-Disease
- IL-2
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2017
Kidney Cancer Trial run by the NCI (117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5
Terminated
- Kidney Cancer
- 117-126:Fibroblast growth factor 5 (FGF-5)
- +2 more
-
Bethesda, MarylandNational Cancer Institute (NCI)
Jul 3, 2017
Neuroblastoma, Lymphoma, High-risk Tumor Trial in Memphis (biological, drug, device)
Completed
- Neuroblastoma
- +2 more
- CD133+ selected autologous stem cell infusion
- +13 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Dec 21, 2017
Metastatic Renal Cell Carcinoma Trial in Lebanon (DC vaccine, Bevacizumab, IL-2)
Terminated
- Metastatic Renal Cell Carcinoma
- DC vaccine
- +3 more
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Oct 28, 2015